Final Program
h6okmgq
h6okmgq
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
MONDAY • MAY 16 137<br />
B5<br />
BASIC • TRANSLATIONAL<br />
BASIC SCIENCE CORE<br />
CME Credits Available: 2.0<br />
HARNESSING BREAKTHROUGHS IN CRISPR GENE<br />
EDITING TECHNOLOGY FOR RESEARCH AND<br />
THERAPY<br />
Assemblies on Respiratory Cell and Molecular Biology; Allergy,<br />
Immunology and Inflammation; Microbiology, Tuberculosis and Pulmonary<br />
Infections; Respiratory Structure and Function; Thoracic Oncology<br />
9:00 a.m. - 11:00 a.m. MOSCONE CENTER<br />
Room 2009/2011 (West Building, Level 2)<br />
Target Audience<br />
Basic and translational researchers seeking to understand the most important<br />
advance in biotechnology in the last decade and clinical investigators and<br />
clinicians interested in learning more about this technology that is poised to<br />
move into clinical application in the coming decade.<br />
Objectives<br />
At the conclusion of this session, the participant will be able to:<br />
• learn new findings about the CRISPR system functions and how it can be<br />
adapted to edit human and other animal genomes;<br />
• improve lung research by learning new strategies for selectively turning<br />
genes on and off, creating lung cancer models, performing genome-wide<br />
screens, and imaging the genome;<br />
• contribute to conversations that will shape scientific and ethical approaches<br />
to the use of CRISPR technology to treat human disease.<br />
The development of the CRISPR system for efficient and selective editing of the<br />
human genome represents the most important scientific breakthrough of the<br />
past decade. CRISPR-based systems are already being widely used for<br />
inactivating or repairing individual genes in human cells and animal models and<br />
for genome-wide studies of the functions of coding and non-coding RNAs. This<br />
session will introduce the basic CRISPR/Cas9 system, explain how this<br />
technology is being modified to allow selective inactivation, activation, and live<br />
imaging of the genome, and illustrate how the technology can be applied to<br />
study and treat lung diseases, including cancer.<br />
Chairing: D. Erle, MD, San Francisco, CA<br />
S. Albelda, MD, Philadephia, PA<br />
N. Chandel, PhD, Chicago, IL<br />
9:00 CRISPR: From Biology to Transformative Technology<br />
J. Corn, PhD, Berkeley, CA<br />
9:30 Genome-Scale CRISPR-Mediated Control of Gene Repression<br />
and Activation<br />
J. Weissman, PhD, San Francisco, CA<br />
10:00 Dissecting the Role of Oxidative Homeostasis in Lung Cancer<br />
Using CRISPR/Cas9 Genome Engineering<br />
T. Papagiannakopoulos, PhD, New York, NY<br />
10:30 CRISPR Tools for Complex Transcription Control and<br />
Functional Study<br />
S. Qi, PhD, Stanford, CA<br />
This session and the International Conference are supported by an educational grant from<br />
AstraZeneca LP.<br />
All CME sessions have been planned and implemented in accordance with the Essential<br />
Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME)<br />
and are free of the control of commercial interests.<br />
B6<br />
BEHAVIORAL • CLINICAL<br />
SCIENTIFIC SYMPOSIUM<br />
CME Credits Available: 2.0<br />
BUILDING E-BRIDGES: TOOLS AT OUR FINGERTIPS<br />
FOR ENHANCING COLLABORATIVE CARE<br />
Assemblies on Behavioral Science and Health Services Research;<br />
Clinical Problems; Critical Care; Nursing; Thoracic Oncology<br />
9:00 a.m. - 11:00 a.m. MOSCONE CENTER<br />
Room 303/305 (South Building, Esplanade Level)<br />
Target Audience<br />
Clinicians and scientists seeking to understand developments in shared<br />
decision-making and to explore cutting edge tools aimed at advancing<br />
interdisciplinary, patient centered collaboration across pulmonary and critical care.<br />
Objectives<br />
At the conclusion of this session, the participant will be able to:<br />
• present new findings about the complexity of shared decision-making to<br />
enhance patient-centered care;<br />
• apply novel, innovative tools to enrich risk communication and improve the<br />
quality of life and health of patients;<br />
• evaluate future directions in and barriers to collaborative, personalized care.<br />
For most medical decisions, multiple options are available with each choice having<br />
its own list of benefits and harms. Decisions inconsistent with patient preferences<br />
may have unintended consequences to both patients and the health system. Shared<br />
decision-making provides a model for personalized medicine to enhance<br />
patient-centered care. This session will allow leading experts to discuss: (1) how<br />
traditional communication has failed and why shared decision-making has evolved;<br />
(2) the complexity of the decision-making process; (3) what tools are available,<br />
across pulmonary and critical care, to enhance communication; (4) what future<br />
directions and barriers may lie ahead in patient-centered risk communication.<br />
Chairing: T.S. Valley, MD, Ann Arbor, MI<br />
R.S. Wiener, MD, MPH, Boston, MA<br />
C.E. Cox, MD, MPH, Durham, NC<br />
9:00 A Patient’s Perspective<br />
K. Erickson, Coral Gables, FL<br />
9:05 Helping Me Help You: Making the Right Decision for Different<br />
Patients<br />
T.S. Valley, MD, Ann Arbor, MI<br />
9:23 So You’re Telling Me There’s a Chance? Theories to Improve<br />
Risk Communication<br />
J.L. Hart, MD, Philadelphia, PA<br />
MONDAY MORNING<br />
ATS 2016 • San Francisco